Compare TKO Group Holdings Inc (TKO) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TKO Group Holdings Inc vs State Street SPDR S&P Biotech ETF — how do they compare? TKO Group Holdings Inc trades at $191.08 (market cap $14.28B), while State Street SPDR S&P Biotech ETF trades at $159.93. The key difference: TKO Group Holdings Inc pays a 1.62% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, TKO Group Holdings Inc nearer its low. Which is the better fit depends on your goals.
| TKO | XBI | |
|---|---|---|
Market Cap | $14.28B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $224.96 | $169.55 |
52-Week Low | $176.49 | $93.43 |
Enterprise Value | $18.64B | — |
Dividend Yield | 1.62% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TKO trades at $195.32, up 5.01% today, with a bullish technical outlook and strong analyst support. Recent Q2 2026 earnings showed revenue growth to $1.5 billion, though EPS missed expectations. The company benefits from media rights strength in UFC and WWE, with revenue projected to rise to $5.3 billion in 2026. Positive sentiment is driven by dividend declarations and conference participation.
The outlook is positive with a consensus price target of $228.17, implying 17% upside. Risks include earnings volatility and competitive pressures in sports entertainment. Institutional ownership trends and bullish analyst ratings (89% buy) support a favorable investment case, but investors should monitor execution on guidance.
XBI trades at $161.97, down 1.12% today, with technical indicators showing mixed signals amid a bearish overall trend. The ETF holds over 150 biotech companies and has rallied 76% in the past year, driven by M&A activity and positive clinical trial catalysts. Analyst coverage remains limited with a single hold rating, while recent news highlights sector optimism around cancer vaccine breakthroughs and improved capital access.
Outlook remains cautiously optimistic with potential for 8-14% returns over 6-12 months, though high volatility and regulatory risks persist. Key opportunities include ongoing pharmaceutical M&A and innovation in immunotherapy, while risks center on sector-specific volatility and policy uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TKO Group Holdings Inc
TKO Group Holdings is a premium sports and entertainment company that serves as the parent entity for the Ultimate Fighting Championship (UFC) and World Wrestling Entertainment (WWE). Formed through a seismic merger orchestrated by Endeavor, TKO leverages a combined global fanbase of over 1 billion to drive massive revenue through media rights, global live events, and a unified sponsorship platform, effectively monopolizing the professional combat sports landscape.
Read more on TKO →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
